Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $369.95
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 7, 26 |
| RBC Capital |
| maintain |
| Outperform |
| Outperform |
| Aug 5, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Aug 5, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 5, 26 | Citigroup | maintain | Neutral | Neutral |
| May 1, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Apr 7, 26 | Citigroup | downgrade | Buy | Neutral |
| Feb 16, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Oct 30, 25 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Oct 30, 25 | Citigroup | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | BIO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 44.4x | -1.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 37.9x | EPS est. 9.75 | In line |
| Price / Book | 1.4x | 1.3x | In line |
| Price / Sales | 3.8x | 4.5x | Discount |
| EV / EBITDA | 20.6x | -2.4x | Discount |
| Return on equity | 3.2% | — | Weak |
| Gross margin | 51.9% | 54.2% | In line |
| Debt / Equity | 0.17 | 0.15 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 3.64 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 53.06 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 40.65 | Oscillator | Neutral |
| Williams %R (14) | -46.94 | Oscillator | Neutral |
| MACD (12, 26, 9) | -2.80 (Hist 0.05) | Oscillator | Buy |
| Average Directional Index (14) | 18.96 (+DI 15.7 / -DI 19.6) | Trend | Neutral |
| EMA 20 | 365.23 | MA | Buy |
| SMA 20 | 365.66 | MA | Buy |
| EMA 50 | 362.30 | MA | Buy |
| SMA 50 | 373.00 | MA | Sell |
| SMA 200 | 311.97 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 20, 26 | Evran Sedat | officer: EVP, Global Supply Chain | M-Exempt | 1,044 | — |
| Oct 20, 26 | Evran Sedat | officer: EVP, Global Supply Chain | F-InKind | 487 @ $354.50 | $172.6K |
| Oct 20, 26 | Evran Sedat | officer: EVP, Global Supply Chain | M-Exempt | 1,044 | — |
| Sep 6, 26 | Allison Schwartz | director | M-Exempt | 92 | — |
| Sep 5, 26 | Allison Schwartz | director | M-Exempt | 228 | — |
| Sep 6, 26 | Allison Schwartz | director | F-InKind | 34 @ $386.11 | $13.13K |
| Sep 5, 26 | Allison Schwartz | director | F-InKind | 82 @ $386.11 | $31.66K |
| Sep 4, 26 | Allison Schwartz | director | A-Award | 719 | — |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
BIO-key (BKYI) secured another Middle East government contract (new customer) for its passwordless, biometric, identity & access management (IAM) solutions
On October 16, 2026, Bio-Rad Laboratories Inc (BIO) shares fell by 3.0%, bringing the current price to $353.70. The stock has experienced a 52-week range of $23
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the.
HOLMDEL, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and tokenless Identity-Bound Biometric™ (IBB) authentication, today announced the appointment of Stephen Morrow as President of PortalGuard®, the Company's flagship IAM platform.
BIO-key (BKYI) Adds New Middle East Government Security Agency, Expands Regional Footprint, Supports National Digital Transformation & Cybersecurity goals.
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
Oncotelic's AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif.
BIO-key (BKYI) Partners with Al Majlis Group, Founded by His Excellency Dherar Belhoul Al Falasi, to Expand Identity Security Across Arabian Gulf Region.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 1.75 | 2.62 | Beat 49.7% | $651.0M |
| Apr 30, 2026 | 1.97 | 1.89 | Miss -4.1% | $592.1M |
| Feb 12, 2026 | 2.57 | 2.51 | Miss -2.3% | $693.2M |
| Oct 29, 2025 | 2.30 | 2.26 | Miss -1.7% | $653.0M |
| Jul 31, 2025 | 1.93 | 2.61 | Beat 35.2% | $651.6M |
| May 1, 2025 | 1.73 | 2.54 | Beat 46.8% | $585.4M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 22, 2026 | 2026-10-22 17:55:06 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:47:17 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:46:53 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:46:26 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:45:58 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:45:28 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:45:01 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:44:28 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:42:51 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:42:11 | View |
Proxy statement (DEF 14A) disclosures